特发性肺纤维化
基质金属蛋白酶
药效团
化学
药理学
病态的
纤维化
基质金属蛋白酶抑制剂
医学
生物信息学
内科学
生物化学
肺
生物
作者
Lin Yang,Yaojie Shi,Xingping Su,Liang Ouyang,Guan Wang,Tinghong Ye
标识
DOI:10.1016/j.ejmech.2021.113714
摘要
Idiopathic pulmonary fibrosis (IPF) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Matrix metalloproteinases (MMPs), promising targets for the treatment of IPF, have been identified as playing a pivotal role in IPF. Although the pathological processes of MMPs and IPF have been verified, there are no MMP inhibitors for the treatment of IPF in the clinic. In this review, we will present the latest developments in MMP inhibitors, including pharmacophores, binding modes, selectivity and optimization strategies. In addition, we will also discuss the future development direction of MMP inhibitors based on emerging tools and techniques.
科研通智能强力驱动
Strongly Powered by AbleSci AI